<?xml version="1.0" encoding="UTF-8"?>
<ref id="B135-molecules-26-03005">
 <label>135.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Widmer</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Bardin</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Chatelut</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Paci</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Beijnen</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Levêque</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Veal</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Astier</surname>
    <given-names>A.</given-names>
   </name>
  </person-group>
  <article-title>Review of therapeutic drug monitoring of anticancer drugs part two—Targeted therapies</article-title>
  <source>Eur. J. Cancer</source>
  <year>2014</year>
  <volume>50</volume>
  <fpage>2020</fpage>
  <lpage>2036</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ejca.2014.04.015</pub-id>
  <pub-id pub-id-type="pmid">24928190</pub-id>
 </element-citation>
</ref>
